ZEN003694
Showing 1 - 15 of 15
Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 Trial (drug,
Not yet recruiting
- Metastatic Colorectal Adenocarcinoma
- +2 more
- BET Bromodomain Inhibitor ZEN-3694
- +6 more
- (no location specified)
Oct 25, 2023
Hematopoietic and Lymphoid System Tumor, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Tumor Trial (BET
Not yet recruiting
- Hematopoietic and Lymphoid System Neoplasm
- +5 more
- BET Bromodomain Inhibitor ZEN-3694
- +6 more
- (no location specified)
Apr 6, 2023
Metastatic Malignant Solid Tumor, Metastatic NUT Carcinoma, Unresectable Malignant Solid Tumor Trial (Abemaciclib, BET
Suspended
- Metastatic Malignant Solid Neoplasm
- +3 more
- Abemaciclib
- +3 more
-
Boston, MassachusettsDana-Farber - Harvard Cancer Center LAO
Sep 17, 2022
Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor Trial in Boston, Galveston,
Suspended
- Advanced Malignant Solid Neoplasm
- +4 more
- BET Bromodomain Inhibitor ZEN-3694
- Binimetinib
-
Boston, Massachusetts
- +2 more
Oct 5, 2022
Advanced Malignant Solid Tumor, Advanced Ovarian Carcinoma, Metastatic Malignant Solid Tumor Trial (BET Bromodomain Inhibitor
Recruiting
- Advanced Malignant Solid Neoplasm
- +7 more
- BET Bromodomain Inhibitor ZEN-3694
- Talazoparib
-
Atlanta, Georgia
- +2 more
Nov 3, 2022
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer Trial in Pittsburgh (ZEN003694, Talazoparib)
Recruiting
- Ovarian Cancer
- +2 more
- ZEN003694
- Talazoparib
-
Pittsburgh, PennsylvaniaUniversity of Pittsburgh Medical Center
Apr 27, 2022
Squamous Cell Lung Cancer Trial in United States (ZEN003694)
Recruiting
- Squamous Cell Lung Cancer
- ZEN003694
-
Basking Ridge, New Jersey
- +6 more
Nov 1, 2022
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Triple-Negative Breast
Not yet recruiting
- Anatomic Stage III Breast Cancer AJCC v8
- +4 more
- BET Bromodomain Inhibitor ZEN-3694
- +3 more
- (no location specified)
Jun 28, 2022
Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Recurrent Platinum-Resistant Ovarian Carcinoma Trial in
Recruiting
- Metastatic Malignant Solid Neoplasm
- +3 more
- BET Bromodomain Inhibitor ZEN-3694
- +2 more
-
Bethesda, Maryland
- +4 more
Aug 16, 2022
Advanced Lymphoma, Advanced Malignant Solid Tumor, Advanced Pancreatic Carcinoma Trial in New Haven (BET Bromodomain Inhibitor
Recruiting
- Advanced Lymphoma
- +13 more
- BET Bromodomain Inhibitor ZEN-3694
- +2 more
-
New Haven, ConnecticutYale University Cancer Center LAO
Jun 29, 2022
Metastatic Castration-Resistant Prostate Cancer Trial in China, United States (ZEN003694, Enzalutamide)
Recruiting
- Metastatic Castration-Resistant Prostate Cancer
- ZEN003694
- Enzalutamide
-
San Francisco, California
- +21 more
Aug 18, 2022
Metastatic Castration-Resistant Prostate Cancer Trial in United States (ZEN003694, Enzalutamide)
Completed
- Metastatic Castration-Resistant Prostate Cancer
- ZEN003694
- Enzalutamide
-
Los Angeles, California
- +7 more
Nov 2, 2021
Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid
Not yet recruiting
- Recurrent Endometrial Carcinoma
- +8 more
- BET Bromodomain Inhibitor ZEN-3694
- +7 more
- (no location specified)
Jul 15, 2023
Metastatic Castration-Resistant Prostate Cancer Trial in United States (ZEN003694)
Completed
- Metastatic Castration-Resistant Prostate Cancer
- ZEN003694
-
Los Angeles, California
- +7 more
Nov 16, 2017